Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
1.710
+0.090 (5.56%)
At close: Nov 13, 2026, 4:00 PM EST
1.720
+0.010 (0.58%)
After-hours: Nov 13, 2026, 7:30 PM EST
Lipocine Revenue
Lipocine had revenue of $2.29M in the quarter ending September 30, 2026, with 1,898.77% growth. This brings the company's total for the last twelve months to $3.74M, down -13.37% year-over-year. In the year 2025, Lipocine had annual revenue of $1.98M, down -82.35%. That makes Lipocine the 40,841st largest company in the world by revenue and 5,460th in the United States.
Revenue (ttm)
$3.74M
Revenue Growth
-13.37%
P/S Ratio
5.06
Revenue / Employee
$267,497
Employees
14
Market Cap
18.94M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.98M | -9.22M | -82.35% |
| Dec 31, 2024 | 11.20M | 8.13M | 264.67% |
| Dec 31, 2023 | 3.07M | 2.57M | 514.16% |
| Dec 31, 2022 | 500.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 164.99K | -263.04K | -61.45% |
| Dec 31, 2018 | 428.03K | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 7.71M | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aligos Therapeutics | 33.65M |
| Kyntra Bio | 4.62M |
| Dyadic International | 3.80M |
| Seres Therapeutics | 2.13M |
| Daré Bioscience | 1.37M |
| Neuphoria Therapeutics | 1.17M |
| Pluri | 1.02M |
| Allarity Therapeutics | 345.00K |
LPCN News
- 4 days ago - Lipocine doses first patient in Phase 3 study evaluating LPCN 1154 - TheFly
- 4 days ago - Lipocine Doses First Participant in BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression - PRNewsWire
- 9 days ago - Lipocine Announces Financial Results for the Third Quarter of 2026 - PRNewsWire
- 9 days ago - Lipocine Quarterly report: Q3 2026 - Filings
- 9 days ago - Lipocine Earnings release: Q3 2026 - Filings
- 25 days ago - Lipocine Slides: Corporate presentation - Filings
- 5 weeks ago - 3 Penny Stocks to Watch Today, October 8 - TipRanks
- 5 weeks ago - Lipocine announces Health Canada approved TLANDO capsules - TheFly